BioLargo (BLGO) Q3 2025 earnings summary

Executive summary

• Portfolio approach focused on cleantech innovation, targeting sustainability and human health through advanced technologies in energy, medical, air quality, and water treatment, with a capital-conserving strategy and high-impact goals.

• Significant progress in commercializing Clyra Medical and battery technology, with Clyra nearing market launch and battery tech validated by third-party.

• Pooph-related setbacks led to a major credit loss, legal action, and license revocation, but the underlying technology is being repositioned.

• PFAS water treatment technology achieved technical breakthroughs, including 90% energy reduction and contaminant removal to less than 4 ppt, with major projects and strategic negotiations underway.

• Management expresses substantial doubt about the ability to continue as a going concern without additional capital or increased revenues.

Financial highlights

• Q3 2025 revenue was $1.21M, down from $4.35M in Q3 2024; nine-month revenue fell 49% year-over-year to $7.1M, mainly due to Pooph.

• Net loss for Q3 2025 was $7.14M, and for the nine months was $11.0M, driven by a $3.85M Pooph impairment and lower sales.

• SG&A expenses increased to $8.3M for the nine months, partly due to Clyra's headcount doubling and non-cash stock expenses.

• Cash position at quarter end was $4.5M, with total assets over $9M and stockholders' equity above $3M.

• Gross margin for the nine months was 46%, down from 43% in the prior year.

Outlook and guidance

• Clyra Medical is preparing for commercialization in late 2025 or early 2026, with first product orders and shipments expected before year-end, pending production and regulatory timelines.

• Clinical data for Clyra products to be published in Q1, supporting broader market adoption.

• Battery technology (Cellinity) targets grid-scale energy storage, with MOUs signed in multiple regions and a future valuation target exceeding $2.5B.

• PFAS projects, including Lake Stockholm, are set to go live soon, with significant revenue potential from over $200M in bids.

• Management expects annual revenues for 2025 to decrease compared to 2024 due to the loss of the Pooph business.